This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)(Learn how and when to remove this template message)
In the field of pharmacology, potency is a measure of drug activity expressed in terms of the amount required to produce an effect of given intensity. A highly potent drug (e.g., fentanyl, alprazolam, risperidone) evokes a given response at low concentrations, while a drug of lower potency (codeine, diazepam, ziprasidone) evokes the same response only at higher concentrations. The potency depends on both the affinity and efficacy.
Affinity is the ability of the drug to bind to a receptor. Efficacy is the relationship between receptor occupancy and the ability to initiate a response at the molecular, cellular, tissue or system level. The response is equal to the effect, or (E), and depends on both the drug binding and the drug-bound receptor then producing a response; thus, potency depends on both affinity and efficacy. The agonist, the ligand, drug or hormone that binds to the receptor and initiates the response is usually abbreviated A or D. Below a certain concentration of agonist ([A]), E is too low to measure but at higher concentrations it becomes appreciable and rises with increasing agonist concentration [A] until at sufficiently high concentrations it can no longer be increased by raising [A] and asymptotes to a maximum Emax.
The Emax is the maximum possible effect for the agonist. The concentration of A at which E is 50% of Emax is termed the half maximal effective concentration and is abbreviated [A]50, or more commonly EC50. The term "potency" refers to the [A]50 value. The lower the [A]50, the less the concentration of a drug is required to produce 50% of maximum effect and the higher the potency.
Higher potency does not necessarily mean more side effects.
The pharmacophore is the part of the drug molecule - the atoms and groups - that bind to the receptor; the "auxophore" are the parts of the molecule that are not directly involved in binding, but may rather interfere with binding, be essential for the arrangement of pharmacophoric elements, or may be irrelevant.:17
- Neubig, RR; Spedding, M; Kenakin, T; Christopoulos, A; International Union of Pharmacology Committee on Receptor Nomenclature and Drug, Classification (December 2003). "International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology.". Pharmacological reviews. 55 (4): 597–606. doi:10.1124/pr.55.4.4. PMID 14657418.
- Silverman, Richard B. (2004). The Organic Chemistry of Drug Design and Drug Action. Academic Press. ISBN 978-0-12-643732-4.
- Harris, Robert (2012-10-09). "Formulating High Potency Drugs". Contract Pharma. Retrieved 2013-11-13.
- Walker MG, Page CP, Hoffman BF, Curtis M (2006). Integrated Pharmacology (3rd ed.). St. Louis: Mosby. ISBN 0-323-04080-2.
|This pharmacology-related article is a stub. You can help Wikipedia by expanding it.|